Vaccine against RSV
AssigneeJanssen Vaccines & Prevention B.V.
InventorsJohannes Petrus Maria Langedijk, Dirk André Emmy Roymans
Life of this patent
Estimating the term…
Abstract
Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.
Claims8
An adenovirus type 26 (Ad26) vector comprising a nucleic acid molecule encoding a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide, wherein, as compared to a wild type RSV F polypeptide, the recombinant RSV F polypeptide comprises:
- (i) a mutation of the amino acid at position 486 from aspartic acid (D) to asparagine (N), and
- (ii) at least one of
- a. a mutation of the amino acid residue at position 67 from asparagine (N) or threonine (T) to isoleucine (I), and
- b. a mutation of the amino acid residue at position 215 from serine (S) to proline (P).
Dependencies are inferred from the claim text.